 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Seattle Genetics, Inc.
 |
Seattle Genetics, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Seattle Genetics reports narrower second-quarter loss Jul 24 2001 01:49 PM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
IPO Weekly: Loudcloud Hits the Street
Mar 09 2001 03:55 PM PST
Loudcloud IPO May Raise Less Than Planned
Mar 08 2001 09:53 AM PST
IPO Weekly: A Loudcloud on the Horizon
Mar 02 2001 02:25 PM PST
PROFILE |
 |
This battle in Seattle isn't about world trade. Seattle Genetics is working on monoclonal antibodies to treat a variety of cancers. Since most monoclonal antibodies (proteins that can target specific cells and bind to molecules) are not potent enough to fight cancer alone, they are often used in conjunction with other drugs. The development-stage firm's lead product candidates, SGN-15 and SGN-10, are being developed to treat breast, colon, lung, prostate, and other cancers, in combination with Aventis' oncology drug Taxotere. Other drugs in development target metastic melanoma and cancers afflicting blood and its components. Its partners include Genentech.
COMPETITION |
 |
Corixa Corporation (CRXA)
IDEC Pharmaceuticals Corporation (IDPH)
Protein Design Labs, Inc. (PDLI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (90.0)%
Employees: 46
Revenue per employee: $2,173.91
KEY PEOPLE |
 |
H. Perry Fell
CEO
Tim J. Carroll
CFO
CONTACT INFO |
 |
22215 26th Ave. SE, Ste. 3000
Bothell, WA 98021
US
Phone: 425-489-4990
Fax: 425-489-4798
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |